Gerhard Fuchs, MD

Professor of Clinical Urology

Executive Director of the USC Institute of Urology (Beverly Hills)

Vice Chair of Education of the USC Institute of Urology

Director of Quality Assurance/Improvement of the USC Institute of Urology

Executive Director of the Men's Health Center

Image of Gerhard Fuchs, MD
Is this your profile? Click to edit

Overview

An internationally renowned surgeon, researcher, and educator with nearly 30 years of experience, Dr. Gerhard J. Fuchs specializes in minimally invasive procedures for treating kidney stones, as well as advanced endoscopic and urologic laparoscopic surgery.

Prior to joining USC, Dr. Fuchs served as the director of the Minimally Invasive Urology Program, Vice Chairman of Department of Surgery, Director for the Urology Residency and Fellowship programs, and the Medallion Chair in Minimally Invasive Urology at Cedars-Sinai Medical Center. Dr. Fuchs also was a clinical professor of urology at the David Geffen School of Medicine at the University of California Los Angeles (UCLA). Previously, Dr. Fuchs held a number of positions at UCLA, including Chief of Endourology, Stone Disease, and Laparoscopic Surgery.

Dr. Fuchs received both his undergraduate and medical degrees from University of Heidelberg in Germany. There he completed his internship in medicine, surgery and gynecology. He was awarded a doctoral degree by the University of Freiburg Medical School, Germany (the equivalent of a PhD in Europe). Residencies in General Surgery and Urology were completed at Tubingen University Medical School in Stuttgart, Germany. He is Board Certified through both the American and German Boards of Urology, and is a Fellow of the American College of Surgeons.

Publications

  • Improving readability of layperson abstracts and summaries in oncology using task-specific large language model powered tool: results from the BRIDGE-AI 7 study. JAMIA Open. 2026 Jun; 9(3):ooag082.. View in PubMed
  • Readability Optimization of Layperson Summaries in Urological Oncology Clinical Trials: Outcomes from the BRIDGE-AI 8 Study. Curr Oncol. 2025 Dec 10; 32(12).. View in PubMed
  • Reply to Jue et al. Overcoming Understaging and Undergrading in Upper Tract Urothelial Carcinoma. Comment on “Ghoreifi et al. Modern Kidney-Sparing Management of Upper Tract Urothelial Carcinoma. Cancers 2023, 15, 4495”. Cancers (Basel). 2024 Feb 29; 16(5).. View in PubMed
  • The Impact of Telemedicine in Reducing the Carbon Footprint in Health Care: A Systematic Review and Cumulative Analysis of 68 Million Clinical Consultations. Eur Urol Focus. 2023 11; 9(6):873-887.. View in PubMed
  • Modern Kidney-Sparing Management of Upper Tract Urothelial Carcinoma. Cancers (Basel). 2023 Sep 10; 15(18).. View in PubMed
  • Reply by Authors. J Urol. 2023 05; 209(5):862.. View in PubMed
  • A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study. J Urol. 2023 05; 209(5):854-862.. View in PubMed
  • The impact of male infertility faculty on urology residency training. Andrologia. 2022 Sep; 54(8):e14457.. View in PubMed
  • Bladder Recurrence Following Diagnostic Ureteroscopy in Patients Undergoing Nephroureterectomy for Upper Tract Urothelial Cancer: Is Ureteral Access Sheath Protective? Urology. 2022 02; 160:142-146. D . View in PubMed
  • Digital urologic education during COVID-19: the rise of the “webin-era”. Minerva Urol Nephrol. 2021 04; 73(2):137-140.. View in PubMed